FDA to streamline approvals of generic biologic drugs

2026 is shaping up to be a make-or-break year for #BigPharma. The U.S. Food and Drug Administration is lining up major drug decisions for Novo Nordisk, Eli Lilly, Merck, and Takeda — rulings that could reshape #cancer care, #obesity treatment, pricing, and patient access. Approvals or delays here won’t just move stocks — they’ll change #medicine itself. #FDA #DrugApprovals #PharmaNews #HealthPolicy #Biotech #Oncology #RareDisease #MetabolicHealth #AIinMedicine #HealthcareMarkets #BreakingNews #F

The FDA Approved Hundreds of Drugs Without Proof They Work

FDA to present data it claims ties Covid shots to child deaths at CDC meeting

Drug makers prepare for emergency FDA approval

Definition of a Drug (April 2017)

GMO Crops, Animal Food, and Beyond